BRPI0411985A - treatment of sexual dysfunction - Google Patents

treatment of sexual dysfunction

Info

Publication number
BRPI0411985A
BRPI0411985A BRPI0411985-1A BRPI0411985A BRPI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
sexual
dysfunction
disorder
Prior art date
Application number
BRPI0411985-1A
Other languages
Portuguese (pt)
Inventor
Alasdair Mark Naylor
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0316673A external-priority patent/GB0316673D0/en
Priority claimed from GB0318095A external-priority patent/GB0318095D0/en
Priority claimed from GB0321308A external-priority patent/GB0321308D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0411985A publication Critical patent/BRPI0411985A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DA DISFUNçãO SEXUAL". A presente invenção refere-se com a utilização de inibidores de guanosina-3<39>,5<39>-monofosfato cíclico-fosfodiesterase de tipo cinco (PDE5), associados a agonistas de 5HT1a para o tratamento de disfunção sexual, em particular do distúrbio da excitação sexual feminina (FSAD) com distúrbio do desejo sexual hipoativo (HSDD) concomitante."Treatment of Sexual Dysfunction". The present invention relates to the use of guanosine-3 ?, 5? -Cyclic monophosphate-phosphodiesterase type five (PDE5) inhibitors, combined with 5HT1a agonists for the treatment of sexual dysfunction, in particular the treatment of sexual dysfunction. female sexual arousal disorder (FSAD) with concomitant hypoactive sexual desire disorder (HSDD).

BRPI0411985-1A 2003-07-16 2004-07-12 treatment of sexual dysfunction BRPI0411985A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0316673A GB0316673D0 (en) 2003-07-16 2003-07-16 Treatment of female sexual dysfunction
GB0318095A GB0318095D0 (en) 2003-08-01 2003-08-01 Treatment of sexual dysfunction
GB0321308A GB0321308D0 (en) 2003-09-11 2003-09-11 Treatment of sexual dysfunction
PCT/IB2004/002286 WO2005007166A1 (en) 2003-07-16 2004-07-12 Treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
BRPI0411985A true BRPI0411985A (en) 2006-08-29

Family

ID=34084177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411985-1A BRPI0411985A (en) 2003-07-16 2004-07-12 treatment of sexual dysfunction

Country Status (7)

Country Link
EP (1) EP1653966A1 (en)
JP (1) JP2007516949A (en)
BR (1) BRPI0411985A (en)
CA (1) CA2532252A1 (en)
MX (1) MXPA06000623A (en)
TW (1) TW200505410A (en)
WO (1) WO2005007166A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
AR048128A1 (en) * 2003-12-01 2006-04-05 Akzo Nobel Nv A TREATMENT OF SEXUAL DIFUNCTION
CA2563743A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
NZ551356A (en) 2004-05-11 2009-09-25 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
ES2646326T3 (en) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
BRPI0712039A2 (en) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int use of flibanserin for the treatment of postmenopausal sexual desire disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
BRPI0716439B8 (en) 2006-08-14 2021-05-25 Boehringer Ingelheim Int pharmaceutical delivery systems comprising flibanserin, process for preparation and use thereof
BRPI0716436B8 (en) 2006-08-25 2021-05-25 Boehringer Ingelheim Int controlled release system and method for manufacturing it
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
CL2008002693A1 (en) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
EP2695932A1 (en) 2012-08-08 2014-02-12 Ab Nanol Technologies Oy Grease composition
JP2021535195A (en) * 2018-08-07 2021-12-16 アイエルワイエルティー・エルエルシーIlylt, Llc Compositions and Methods for Treating Sexual Dysfunction and Enhancing Sexual Response and Pleasure
IL292775A (en) * 2019-11-08 2022-07-01 Vella Bioscience Inc Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
WO2024173493A1 (en) * 2023-02-14 2024-08-22 Daré Bioscience, Inc. Compositions and methods of treating female sexual dysfunction and female sexual arousal disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055070A1 (en) * 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) * 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
CA2532252A1 (en) 2005-01-27
TW200505410A (en) 2005-02-16
WO2005007166A1 (en) 2005-01-27
MXPA06000623A (en) 2006-04-11
EP1653966A1 (en) 2006-05-10
JP2007516949A (en) 2007-06-28

Similar Documents

Publication Publication Date Title
TW200505410A (en) Treatment of sexual dysfunction
MX2010000098A (en) Polycyclic guanine derivatives and use thereof.
CY1122522T1 (en) META ARSENICODE SODIUM FOR USE IN THE MANAGEMENT OF MULTIPLE MYELOMA
NO20085099L (en) Puriton derivatives such as HM74A agonists
NO20085257L (en) Purinone derivatives as HM74a agonists
NO20072558L (en) Mitotic kinase inhibitors and methods for their use
CL2008002207A1 (en) Pharmaceutical composition comprising immunosuppressants to improve the effect in the use of an antagonist of interleukin-6 (il-6) for the treatment of illnesses related to il-6 (div. Sol. 896-04).
PH12014501440A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
CL2007001318A1 (en) Use of flibanserin, optionally as a free base, hydrate salt or solvate thereof, to prepare a useful medication in the treatment of sexual desire disorders in women.
ECSP11010975A (en) METHOD OF USE OF A BACILLUS SUBTILIS CEPA TO IMPROVE ANIMAL HEALTH
CY1112067T1 (en) USE OF FLIBANSERINE FOR THE TREATMENT OF PRE-MONOPOLY DISORDERS
EA201170288A1 (en) OXABICYCLOPTANES AND OXABICYCLOPTENS
EA200870425A1 (en) APPLICATION OF GRP119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS AND RELATED COMBINED THERAPY
EA201491697A1 (en) COMPOSITIONS OF GUANYLATZIKLAZY AGONISTS AND METHODS OF APPLICATION
BR112016009889A2 (en) gip-glp-1 double agonist compounds and methods
EA200970737A1 (en) OXABICYCLOPTANES AND OXABICYCLOPTENS
PA8846101A1 (en) ANTI-TGF-BETA RECEIVER II ANTIBODIES
PT2334677E (en) Triazolopyridine compounds as pim kinase inhibitors
EA201791843A2 (en) METHODS OF INCREASING THE EFFICIENCY OF FOLR1 CANCER THERAPY
HN2005036256A (en) FUSIONATED DERIVATIVES OF PIRAZOL AND METHODS OF TREATMENT OF METABOLIC DISORDERS WITH THESE
EA200601074A1 (en) APPLICATION OF DERIVATIVE PEPTIDES FOR THE TREATMENT OF PAINS ASSOCIATED WITH THE DISEASE OF THE CENTRAL NERVOUS SYSTEM (CENTRAL NEUROPATHIC PAIN)
UY3512Q (en) HAIR IRON
EA200601391A1 (en) QUINOLINE DERIVATIVES FOR USE AS MYCOBACTERIAL INHIBITORS
CL2008001074A1 (en) Use of triazole compounds, smo antagonists to treat cancer.
AR113492A2 (en) RECOMBINANT FURIN FREE OF SUBSTANTIALLY ANIMAL PROTEINS AND METHODS TO PRODUCE IT

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.